SCHEMBL613270

SCHEMBL613270

CNc1cc(-c2ccncc2)sc1C(=O)OC

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.57
MAPT P10636 6/20 0.57
ALDH1A1 P00352 2/20 0.57
LMNA P02545 1/20 0.57
HPGD P15428 2/20 0.54
IKBKB O14920 2/20 0.51
HTT P42858 1/20 0.51
ATM Q13315 1/20 0.51
NPSR1 Q6W5P4 3/20 0.49
KMT2A Q03164 1/20 0.49
CDC7 O00311 1/20 0.49
DBF4 Q9UBU7 1/20 0.49
TP53 P04637 2/20 0.48
POLB P06746 1/20 0.48
NPC1 O15118 1/20 0.48
CASP3 P42574 1/20 0.48
RAB9A P51151 1/20 0.48
SENP8 Q96LD8 1/20 0.48
SENP7 Q9BQF6 1/20 0.48
SENP6 Q9GZR1 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL611492 0.87 IKBKB (0.52) KDM4EMAPTALDH1A1LMNAIKBKB
SCHEMBL612006 0.86 KDM4E (0.52) KDM4EMAPTALDH1A1LMNAHPGD
SCHEMBL613722 0.86 KDM4E (0.52) KDM4EMAPTALDH1A1LMNAHPGD
SCHEMBL612250 0.85 IKBKB (0.70) IKBKBCDC7DBF4
SCHEMBL2157496 0.85 MAPT (0.76) KDM4EMAPTALDH1A1LMNAHPGD
SCHEMBL613988 0.84 KDM4E (0.50) KDM4EMAPTALDH1A1LMNAHPGD
SCHEMBL23452054 0.84 KDM4E (0.61) KDM4EMAPTALDH1A1LMNAHPGD
SCHEMBL24131780 0.83 NPSR1 (0.57) KDM4EMAPTALDH1A1LMNAHPGD
SCHEMBL613186 0.82 MAPT (0.70) KDM4EMAPTALDH1A1LMNAHPGD
SCHEMBL27029284 0.82 CDC7 (0.49) KDM4EMAPTALDH1A1LMNAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2403857-B1 THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS TAKEDA PHARMACEUTICAL (JP) 2013-12-04 EP disclosed
US-20120040981-A1 THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-02-16 US disclosed
EP-2403857-A1 THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS Takeda Pharmaceutical Company Limited (JP) 2012-01-11 EP disclosed
WO-2010101302-A1 THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120040981-A1 THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS CDC7, CDK7, DTYMK KDM4E 1319/4885MAPT 2979/4885ALDH1A1 1927/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.